Purification of cell culture-derived human influenza A virus by size-exclusion and anion-exchange chromatography

Biotechnology and Bioengineering

Volumn 96, Issue 5, 2007, Pages 932-944

  Kalbfuss, Bernd ^a   Wolff, Michael ^a   Morenweiser, Robert ^b   Reichl, Udo ^a,c  

^a MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

^b BIACORE AB   (Sweden)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Anion exchange chromatography; Cell culture derived; Downstream processing; Human influenza A virus; Size exclusion chromatography; Vaccine

Indexed keywords

CELL CULTURE; DNA; ION EXCHANGE; PURIFICATION; SIZE EXCLUSION CHROMATOGRAPHY; VACCINES;

ANION-EXCHANGE CHROMATOGRAPHY (ABC); DOWNSTREAM PROCESSING; HUMAN INFLUENZA A VIRUS;

VIRUSES;

CELL DNA; INFLUENZA VACCINE; SEPHAROSE; SODIUM CHLORIDE;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CELL CULTURE; CELL STRAIN; CONTROLLED STUDY; CROSSFLOW FILTRATION; DRUG SYNTHESIS; GEL PERMEATION CHROMATOGRAPHY; HEMAGGLUTINATION; INFLUENZA VIRUS A H1N1; NONHUMAN; ULTRAFILTRATION; VIRION; VIRUS PURIFICATION;

ANIONS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, ION EXCHANGE; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE;

HUMAN INFLUENZA VIRUS; INFLUENZA A VIRUS;

EID: 33947611187     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21109     Document Type: Article

References (30)

1. Amosenko FA, Svitkin YV, Popova VD, Terletskaya EN, Timofeev AV, Elbert LB, Lashkevich VA, Drozdov SG. 1991. Use of pratamine sulphate for elimination of substrate DNA in poliovaccines produced on continuous cell lines. Vaccine 9:207-209.
2. Bardiya N, Bae JH. 2005. Influenza vaccines: Recent advances in production technologies. Appl Microbiol Biotechnol 67:299-305.
3. TC: A safe Madine Darby canine kidney (MDCK) cell culture-based influenza vaccine. Dev Biol Stand 98:93-100.
4. Cox HR, Scheer J, Aiston S, Bohnel E. 1947. The purification and concentration of influenza virus by means of alcohol precipitation. J Immunol 56:149-166.
5. Donald HB, Isaacs A. 1954. Counts of influenza virus particles. J Gen Microbiol 10:457-464.
6. Ferreira GNM, Cabral IMS, Prazeres DMF. 2000. Studies on the batch adsorption of plasmid DNA onto anion-exchange chromatographic supports. Biotechnology Progress 16:416-424.
7. Gerdil C. 2003. The annual production cycle for influenza vaccine. Vaccine 21:1776-1779.
8. Geschwender HH, Haller W, Hofschneider PH. 1969. Large-scale preparations of virus by steric chromatography on columns of controlled pore glass. Biochimica et Biophysica Acta 190:460-469.
9. Goerke AR, To BCS, Lee AL, Sagar SL, Konz JO. 2005. Development of a novel adenovirus purification process utilizing selective precipitation of cellular DNA. Biotechnol Bioeng 91:12-21.
10. Heyward JT, Klimas RA, Stapp MD, Obijeski JF. 1977. The rapid concentration and purification of influenza virus from allontoic fluid. Arch Virol 55:107-119.
11. Kalbfuss B, Genzel Y, Wolff M, Zimmermann A, Morenweiser R, Reichl U. 2006. Harvesting and concentration of human influenza A virus produced in serum-free mammalian cell culture for the production of vaccines. Biotechnology and Bioengineering. Published online 18 August 2006 in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/bit.21139.
12. Kistner O, Barret PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. 1998. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16:960-968.
13. Knipe DM, Howley PM. 2001. Fields Virology, Chapter 46: Orthomyxoviridae. Philadelphia: Lippincott Williams & Wilkins.
14. Knudsen HL, Fahrner RL, Xu Y, Norling LA, Blank GS. 2001. Membrane ion-exchange chromatography for process-scale antibody purification. J Chromatogr A 907:145-154.
15. Konz JO, Lee AL, Lewis JA, Sagar SL. 2005. Development of a purification process for adenovirus: Controlling virus aggregation to improve clearance of host cell DNA. Biotechnol Prog 21:466-472.
16. Kumar AAP, Rao YUB, Joseph ALW, Mani KR, Swaminathan K. 2002. Process standardization for optimal virus recovery and removal of substrate DNA and bovine serum proteins in vero cell-derived rabies vaccine. J Biosci Bioeng 94:375-383.
17. Li Z, Gu Y, Gu T. 1998. Mathematical modeling and scale-up of size-exclusion chromatography. Biochem Eng J 2:145-155.
18. Loa CC, Lin TL, Wu CC, Bryan TA, Thacker HL, Hooper T, Schrader D. 2002. Purification of turkey coronavirus by sephacryl size-exclusion chromatography. J Virol Methods 104:187-194.
19. Nayak DP, Lehmann S, Reichl U. 2005. Downstream processing of MDCK cell-derived equine influenza virus. J Chromatogr B 823:75-81.
20. Oxford JS, Corcoran T, Hugentobler AL. 1981. Quantitative analysis of the protein composition of influenza A and B viruses using high resolution SDS polyacrylamide gels. J Biol Stand 9:483-491.
21. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. 2001. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19:2716-2721.
22. Potschka M. 1991. Size-exclusion chromatography of DNA and viruses: Properties of spherical asymmetric molecules in porous networks. Macromolecules 24:5023-5039.
23. Reimer CB, Baker RS, Newlin TE, Havens ML. 1966. Influenza virus purification with the zonal ultracentrifuge. Science 152:1379-1381.
24. Reimer CB, Baker RS, Frank RM, Newlin TE, Cline GB, Anderson NG. 1967. Purification of large quantities of influenza virus by density gradient centrifugation. J Virol 1:1207-1216.
25. Scholtissek C. 1985. Stability of infectious influenza A viruses at low pH and elevated temperature. Vaccine 3:215-218.
26. Segura MM, Kamen A, Trudel P, Garnier A. 2005. A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. Biotechnol Bioeng 90:391-404.
27. Sugawara K, Nishiyama K, Ishikawa Y, Abe M, Sonoda K, Komatsu K, Horikawa Y, Takeda K, Honda T, Kino Y, Mizokami H, Mizuno K, Oka T, Honda K. 2002. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 30:303-314.
28. Transfiguracion J, Jaalouk DE, Ghani K, Galipeau J, Kamen A. 2003. Size-exclusion chromatography purification of high-titer vesicular stomatitis virus G glycoprotein-pseudotyped retrovectors for cell and gene therapy applications. Hum Gene Ther 14:1139-1153.
29. Tree JA, Richardson C, Fooks AR, Clegg C, Looby D. 2001. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19:3444-3450.
30. Wickramasinghe SR, Kalbfuß B, Zimmermann A, Thom V, Reichl U. 2005. Tangential flow microfiltration and ultrafiltration for human influenza A virus: Concentration and purification. Biotechnol Bioeng 92:199-208.